Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Innoviva, Inc.
INVA
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.6B
$22.31
▲ +1.87%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$16.52 - $25.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 12.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary ELLIPTA dry powder inhaler technology enabling once-daily dosing
- Strategic partnership with GSK providing global commercialization and distribution capabilities
- Established market presence in COPD and asthma treatment with proven efficacy and patient adoption
- Patent-protected combination therapies with multiple drug classes addressing unmet patient needs
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Expanding international markets and emerging market penetration for respiratory products
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-4.7% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INVA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 6, 2026
Reported EPS of $0.44 vs $0.43 consensus (+2.3% surprise). Revenue of $98.0M vs $101.6M expected (-3.5%).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+2.3%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
+7%
+14%
-3%
+20%
+29%
+11%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$103.4M
$89.5M
$91.8M
$88.6M
$100.3M
$107.8M
$118.0M
$98.0M
Margins · last 8Q
Gross
—
Operating
—
Profit
190.4%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$42.00
▲ +88.3% vs $22.31
Latest: UBS · Jun 22, 2026
1 analyst covering